Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

Christina M. Wilson, PhD, CRNP, WHNP-BC, shares how providers can help their patients feel empowered during their treatment.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.

The median progression-free survival was not reached with atezolizumab plus chemotherapy vs 6.9 months in the placebo group of patients with advanced or recurrent endometrial cancer.